Reports Q1 revenue $54.24M, consensus $54.1M. Total orders received for the first quarter were $64.7M. "We had a very good start to the year with solid revenue across SynBio, NGS and biopharma as well as robust orders, setting the stage for growth and advancement across the business," said Emily Leproust, CEO and co-founder of Twist Bioscience. "We shipped our first products out of the Factory of the Future last month, expanded our customer base, entered into antibody discovery and optimization partnerships and are nearing completion of our first proof-of-concept scalable DNA data storage writer."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TWST:
- These 2 ‘Oversold’ Stocks Could Be Ready for a Comeback, Say Analysts
- Twist Bioscience price target lowered to $37 from $43 at Barclays
- Twist Centogene launch target enrichment panels for rare disease diagnosis
- Twist in research pact with with Astellas, eligible for milestone payments
- Twist Bioscience initiated with Outperform, $33 target at Scotiabank
